Contact
searchSearch
HMP Global
Login

Myelofibrosis Resource Center

Featured

News
Structural Racism Identified as Key Driver of Survival Disparities in Myelofibrosis
12/12/2025
Lisa Kuhns, PhD, MD
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than...
12/12/2025
Journal of Clinical Pathways
News
Ruxolitinib Plus ESA or Danazol Maintains Efficacy in Patients With Myelofibrosis Who Have Anemia
10/20/2025
Grace Taylor, MS, MA
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase...
10/20/2025
Journal of Clinical Pathways
News
Pacritinib Shows Promising Real-World Benefits for Myelofibrosis With Anemia
10/10/2025
Grace Taylor, MS, MA
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests...
10/10/2025
Journal of Clinical Pathways
Conference Coverage
Projected Cost and Time Savings With Pacritinib in Transfusion-Dependent Myelofibrosis
05/30/2025
Juliet Gallagher
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the...
05/30/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways
News
Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment
02/19/2025
Grace Taylor, MS, MA
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer...
02/19/2025
Journal of Clinical Pathways
News
Study Highlights Momelotinib as a Promising Alternative for Myelofibrosis With Anemia
02/05/2025
Grace Taylor, MS, MA
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Juliet Gallagher
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways

Newsfeed

News
Structural Racism Identified as Key Driver of Survival Disparities in Myelofibrosis
12/12/2025
Lisa Kuhns, PhD, MD
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than biological differences or treatment patterns, appears to drive survival disparities in myelofibrosis (MF) among minority patients, according to a new multicenter analysis, according to study results published in...
Structural racism, rather than...
12/12/2025
Journal of Clinical Pathways
News
Ruxolitinib Plus ESA or Danazol Maintains Efficacy in Patients With Myelofibrosis Who Have Anemia
10/20/2025
Grace Taylor, MS, MA
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase 3b JUMP trial shows that adding erythropoiesis-stimulating agents (ESA) or danazol to ruxolitinib preserves spleen and symptom responses while supporting hemoglobin recovery in patients with myelofibrosis who...
A post-hoc analysis of the phase...
10/20/2025
Journal of Clinical Pathways
News
Pacritinib Shows Promising Real-World Benefits for Myelofibrosis With Anemia
10/10/2025
Grace Taylor, MS, MA
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests that pacritinib may improve or stabilize hemoglobin and platelet counts in patients with myelofibrosis, including those with severe anemia, reinforcing its potential utility in cytopenic populations.
A real-world data study suggests...
10/10/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways
News
Momelotinib Offsets Transfusion-Related Burden and Costs in Myelofibrosis Treatment
02/19/2025
Grace Taylor, MS, MA
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer reveals that momelotinib reduces transfusion costs and time burden for patients with myelofibrosis compared to ruxolitinib and best available therapy.
A study published in Cancer...
02/19/2025
Journal of Clinical Pathways
News
Study Highlights Momelotinib as a Promising Alternative for Myelofibrosis With Anemia
02/05/2025
Grace Taylor, MS, MA
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that momelotinib effectively improves anemia, reduces symptoms, and controls splenomegaly in patients with myelofibrosis, including those previously treated with other JAK inhibitors.
A real-world study shows that...
02/05/2025
Journal of Clinical Pathways
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Juliet Gallagher
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways
News
Real-World Data Support Earlier T-DXd Use in HR+/HER2-Low Metastatic Breast Cancer
03/04/2026
Grace Taylor, MS, MA
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab...
03/04/2026
Journal of Clinical Pathways
News
Neighborhood Socioeconomic Status Tied to Survival in US Early-Onset Metastatic Colorectal Cancer
02/19/2026
Hannah Musick
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort...
02/19/2026
Journal of Clinical Pathways
News
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in Metastatic TNBC
02/13/2026
Grace Taylor, MS, MA
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3...
02/13/2026
Journal of Clinical Pathways
News
Mobile App Self-Acupressure Reduces Ovarian Cancer Fatigue, Study Finds
02/13/2026
Grace Taylor, MS, MA
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided...
02/13/2026
Journal of Clinical Pathways
News
Interlocking Poverty, Stigma, and Information Gaps Drive Hospice Exclusion for Low-Income Cancer Patients
02/13/2026
Lisa Kuhns, PhD, MD
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among...
02/13/2026
Journal of Clinical Pathways
News
Patient Navigation Improves Colorectal Cancer Screening in Washington, DC Safety Net
02/11/2026
Hannah Musick
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC...
02/11/2026
Journal of Clinical Pathways
News
Tumor-Informed ctDNA Surveillance for HCC and CCA After Liver Transplant Shows High Specificity
02/09/2026
Grace Taylor, MS, MA
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed...
02/09/2026
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
Projected Cost and Time Savings With Pacritinib in Transfusion-Dependent Myelofibrosis
05/30/2025
Juliet Gallagher
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the PERSIST-2 trial, presented at ASCO 2025, suggests that pacritinib may offer significant reductions in both cost and time burden associated with red blood cell (RBC) transfusions in patients with myelofibrosis (MF)...
An economic analysis of the...
05/30/2025
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD,...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024
Douglas Tremblay, MD
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting,...
01/03/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023
Grace Taylor, MS, MA
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
Conference Coverage
Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
12/07/2023
Grace Taylor, MS, MA
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS,...
12/07/2023
Journal of Clinical Pathways
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
Yvette C. Terrie, BS Pharm, RPh
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
High-Risk Features Predict Early Relapse After Cilta-Cel Therapy in Relapsed/Refractory Multiple Myeloma
12/18/2025
Grace Taylor, MS, MA
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver...
12/18/2025
Journal of Clinical Pathways
Conference Coverage
Intensive Isa-VRDc Regimen Shows Strong Progression-Free Survival in Double-Hit Myeloma
12/17/2025
Hannah Musick
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Advances in Molecular Diagnostics Transform Care for Cytopenias and Hereditary Anemias
12/16/2025
Grace Taylor, MS, MA
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
Emerging molecular diagnostics are redefining how clinicians evaluate cytopenias, bone marrow failure, and hereditary anemias, enabling more accurate diagnoses and better-informed treatment decisions.
Emerging molecular diagnostics...
12/16/2025
Journal of Clinical Pathways
Conference Coverage
Novel Targeted Approaches Redefine Treatment Pathways in Immune Cytopenias
12/16/2025
Grace Taylor, MS, MA
In a panel presentation at ASH 2025, experts highlight current data on complement activity, B-cell–directed therapies, and personalized approaches for difficult-to-treat immune cytopenias.
In a panel presentation at ASH 2025, experts highlight current data on complement activity, B-cell–directed therapies, and personalized approaches for difficult-to-treat immune cytopenias.
In a panel presentation at ASH...
12/16/2025
Journal of Clinical Pathways
Conference Coverage
Advances in Anticoagulation Strategies for Cancer-Associated Thrombosis
12/15/2025
Grace Taylor, MS, MA
Experts spotlight new evidence shaping the prevention and treatment of cancer-associated thrombosis, with growing emphasis on direct oral anticoagulants (DOACs) and risk-guided care.
Experts spotlight new evidence shaping the prevention and treatment of cancer-associated thrombosis, with growing emphasis on direct oral anticoagulants (DOACs) and risk-guided care.
Experts spotlight new evidence...
12/15/2025
Journal of Clinical Pathways
Conference Coverage
Improving Outcomes in Diffuse Large B-Cell Lymphoma: Molecular Subtypes and Early Response Assessments
12/15/2025
Grace Taylor, MS, MA
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025...
12/15/2025
Journal of Clinical Pathways

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use